BridgeBio Oncology Therapeutics

BBOT Lead: Phase 1 5 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

BBO-8520 readout2H 2026BBO-8520 readout, 2H 2026, major
BBO-10203 readout2H 2026BBO-10203 readout, 2H 2026, major
BBOT pipeline BBO-11818 Ph1 readout2H 2026BBOT pipeline BBO-11818 Ph1 readout, 2H 2026, major
BBO-11818 Ph1 interim2H 2026BBO-11818 Ph1 interim, 2H 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

BBO-11818

Small Molecule Target: KRAS G12D, KRAS G12V, KRAS G12C, panKRAS, KRAS

Non-Small Cell Lung Cancer Phase 1 oral
Colorectal Cancer Phase 1 oral
Pancreatic Ductal Adenocarcinoma Phase 1 oral

BBO-10203

Small Molecule Target: PI3Kα RAS-binding domain, KRAS, RAS, PI3Ka

Colorectal Cancer Phase 1 oral NCT06625775
Non-Small Cell Lung Cancer Phase 1 oral
Pancreatic Ductal Adenocarcinoma Phase 1 oral

Discontinued (2)

BBO-8520 — Non-Small Cell Lung Cancer · strategic deprioritization due to evolving treatment landscape, competitive crowding, and portfolio dynamics
BBO-10203 — Breast Cancer · strategic deprioritization due to evolving treatment landscape, competitive crowding, and portfolio dynamics

Biotech Distilled coverage (5)

2026-09-08 UPDATE: BridgeBio Oncology (BBOT) - The n Finally Moved 🔒 Paid
2026-09-02 UPDATE: BridgeBio Oncology (BBOT) - The ATM Arrives Ninety Days Early 🔒 Paid
2026-08-12 UPDATE: BridgeBio Oncology (BBOT) - The Internal Combo Leaves the Lab 🔒 Paid
2026-04-27 UPDATE: BridgeBio Oncology (BBOT) - The CSO Takes the Wheel, the FDA Hands Out a Hall Pass 🔒 Paid
2026-04-20 BridgeBio Oncology (BBOT) - Scientific Deep Dive for BBO-8520, BBO-11818, and BBO-10203 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.